Search
Search
Close this search box.

London CBD Tampon Entrepreneur Launches With Silicon Valley Cash

AFTER securing a $5.5m investment British start-up Daye has launched its new Femcare range which features a pain-relieving CBD tampon.

Founded in London by 24-year-old Valentina Milanova Daye, it aims to build a new brand of health products designed ‘with women in mind’.

The start-up’s first product is a newly developed tampon that uses CBD to help tackle period cramps – dysmenorrhea – as an alternative to traditional painkillers. 

Supporting the company are Silicon Valley’s Khosla Ventures,  along with London’s Index Ventures and Kindred Capital. 

TechCrunch say Khosla’s chief-of-staff Kristina Simmons and venture partner Tim Westergren – founder of Pandora – and Hannah Seal, principle at Index, have joined Daye’s board.

Other investors include Sophia Bendz, who is the former global director of Marketing at Spotify.

Valentina, originally from Bulgaria, says CBD content allows for the creation of ‘a protective sleeve over the tampon that prevents fibre loss, decreasing the risk of bacterial vaginal infection or Toxic Shock Syndrome’. 

The start-up’s medical board includes two University of Liverpool professors Ian Buchan and Louise Kenny, and Daye has carried out clinical trials in Bulgaria, supported by the Centre for Applied Science and Innovation at Sofia Medical University. 

Valentina says she first had the idea for a cramp-fighting tampon in 2017 and initially used her salary from a day job, and credit cards, to fund its development.

🔒 Risk Management Report • Produced in partnership with RELM
Prohibition Partners RELM
📊 New Report Available Now

Relm Risk Briefing: Cannabis 2026

The global cannabis sector has moved from experiment to enterprise. This comprehensive risk briefing examines how regulation, insurance, and operational practices intersect across the international supply chain, drawing on insights from RELM—the only insurer entirely dedicated to the cannabis industry.

What's covered

  • 🌱 Cultivation risk management — biological contamination, environmental instability, and security protocols
  • ⚗️ Manufacturing & extraction — GMP standards, in-house testing, and quality control measures
  • 🔬 Testing & compliance — rigorous protocols ensuring product safety and regulatory adherence
  • 📦 Distribution & logistics — GDP-aligned transport, route monitoring, and cargo insurance
Key focus areas
Cultivation Manufacturing Testing & QC Packaging Distribution Retail & Pharmacy
100% free • Comprehensive risk analysis

Key insights

Industry Maturity Cannabis has evolved from patchwork markets to international enterprise, with risk management now the measure of long-term stability.
Cultivation Challenges Operators addressing biological contamination through controlled-environment agriculture, tissue culture, and IPM protocols.
Quality Control GMP adherence, in-house testing, and selective supplier relationships emerging as critical control points.
Supply Chain Security GDP-aligned transport, route monitoring, and comprehensive insurance remain essential safeguards.
Market Access Initiatives stabilizing domestic supply and expanding pharmacy training improving patient and consumer access.
Produced by Prohibition Partners in collaboration with RELM—the only insurer dedicated to emerging industries like cannabis.
Partnership
Produced by Prohibition Partners in collaboration with RELM

Related Posts

Related Posts

CONNECT

Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you

Categories

Browse by Tags

CATEGORIES

EDITION

BUSINESS OF CANNABIS

© 2023 Prohibition Holdings Ltd. All Rights Reserved.

EDITION

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?